Physician profile
Anne Rothman
NPI 1437251956
$9,431.05
in general payments reported to CMS, 2019-2025
36 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $435 · 2021: $1,057 · 2022: $1,126 · 2023: $1,603 · 2024: $1,992 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,108 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $883 · Education: $355 · Travel and Lodging: $6.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,107.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $882.77 |
| Education | $355.22 |
| Travel and Lodging | $6.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,192.48 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,026.37 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $749.04 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Lilly USA, LLC | $665.60 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $485.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $476.61 | 2021-2025 | |
| Genzyme Corporation | $442.48 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $364.37 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Ucb, INC. | $334.46 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $330.09 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $241.74 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $217.50 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $191.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.10 | 2022-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $160.68 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $145.60 | 2023-2024 | Vtama |
| Almirall LLC | $138.56 | 2019-2025 | Klisyri |
| Leo Pharma INC. | $137.13 | 2019-2022 | |
| Amgen INC. | $119.13 | 2021-2024 | Otezla |
| Allergan, INC. | $100.87 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $88.46 | 2024-2025 | Zoryve |
| Revance Therapeutics, INC. | $78.35 | 2024 | Daxxify |
| Epi Health, LLC | $78.19 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $77.67 | 2020-2021 | |
| Hill Dermaceuticals, INC. | $76.13 | 2022 | |
| Celgene Corporation | $63.84 | 2019 | |
| Dermira, INC. | $56.97 | 2019-2020 | |
| Organon LLC | $56.04 | 2025 | Vtama |
| Sebela Pharmaceuticals INC. | $37.15 | 2019-2022 | |
| Aclaris Therapeutics, INC. | $23.94 | 2019 | |
| Botanix Sb INC | $21.86 | 2025 | Sofdra |
| Journey Medical Corporation | $18.07 | 2019 | |
| Merz North America, INC. | $16.78 | 2019 | |
| Janssen Scientific Affairs, LLC | $16.41 | 2019 | |
| Biofrontera INC. | $14.86 | 2022 | |
| Prugen, INC. Pharmaceuticals | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.